EGFR and non-small cell lung carcinoma: For example, Hilton et al. reported that antacids did not adversely affect PFS and OS among patients who were receiving TKIs in the second line or later line.[13] In contrast, another study reported that the concomitant use of antacids and EGFR-TKIs shortened the PFS and OS among patients with NSCLC (only 4% of patients were receiving first-line TKIs).[12] However, both studies did not examine the patients’ EGFR mutation status, and most of the patients were receiving TKIs after receiving a different first-line treatment.